Peptide library

What is
retatrutide?

Retatrutide is a drug in development at Eli Lilly that acts on three hormone receptors at once. What the phase 3 trials measured, where it stands with regulators in November 2026, and why products sold online under the name are not the drug in those trials.

Short answerCompound research · 7 min read · Updated 18 Nov 2026

Retatrutide (LY3437943) is a drug in development at Eli Lilly: a single peptide that activates the receptors for three hormones, GIP, GLP-1 and glucagon. It is investigational and not approved anywhere. Its first phase 3 obesity trials appeared in NEJM and The Lancet in September 2026, and Lilly plans to seek US approval in early 2027.

Key takeaways

  • Retatrutide (LY3437943) is a single peptide that activates the GIP, GLP-1 and glucagon receptors; Eli Lilly is developing it and funded every trial on this page.
  • It is investigational and not approved anywhere: the TGA says no comparable international regulator has approved it, and the MHRA says it is not authorised in the UK.
  • The first phase 3 obesity trials, TRIUMPH-1 and TRIUMPH-2, were published in NEJM and The Lancet on 29 September 2026; Lilly plans to submit for US approval in the first quarter of 2027.
  • FDA says retatrutide cannot be used in compounding under federal law, and its August 2026 warning letters list products sold online as retatrutide, including as “GLP-3”, among unapproved new drugs.
  • In November 2026 the TGA’s laboratory found that tested products from one brand, sold as retatrutide, held less than their labels stated, with significant variation between samples.

01Retatrutide at a glance

The short version, dated 18 November 2026.

QuestionRetatrutide
What it isA single peptide that activates three hormone receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1) and glucagon. Lilly calls it a triple hormone receptor agonist.
Other namesLY3437943, its development code. FDA warning letters record sellers listing it as “GLP-3 RT” and “GLP-3R”; no PubMed title or abstract on retatrutide uses “GLP-3” (18 Nov 2026).
DeveloperEli Lilly and Company, which funded every trial on this page.
Evidence tierT1, investigational: randomised, placebo-controlled trials of Lilly’s product, published from 2022 to 2026.
Phase 3 studiesClinicalTrials.gov lists 14, all sponsored by Lilly: 5 completed, 9 active or recruiting.
United StatesNot approved. FDA says it “cannot be used in compounding under federal law”. Lilly plans to submit an application for approval in the first quarter of 2027.
United KingdomMHRA, 15 Oct 2026: “Retatrutide has not been authorised for use in the UK.”
AustraliaTGA, 5 Nov 2026: not approved “by the TGA or any comparable international regulator”.

02What retatrutide is, and where “GLP-3” comes from

Retatrutide is one peptide that activates three hormone receptors: the receptors for GIP and GLP-1, and the receptor for glucagon. That is why the papers call it a triple agonist. Early human results were published in 2022 under its code, LY3437943, including a 12-week phase 1b trial of 72 adults with type 2 diabetes, randomised against placebo, whose primary outcome was safety and tolerability.

“GLP-3” is not a name the research uses for retatrutide: no PubMed title or abstract on retatrutide uses it (18 Nov 2026), and the trial papers we cite call it retatrutide or LY3437943. The label comes from sellers. FDA warning letters dated 24 August 2026 record products listed as “Retatrutide (GLP-3 RT)”, “GLP-3 RT (Retatrutide) Research Peptide” and “GLP-3R”, sold alongside products listed as “Semaglutide (GLP-1 SEM)” and “Tirzepatide (GLP-2 TRZ)”.

03What the phase 3 trials measured

Lilly’s phase 3 obesity programme is called TRIUMPH. Its first results papers appeared between September and November 2026.

Each trial below was randomised, placebo-controlled and funded by Lilly. We list who took part and what each trial set out to measure. We do not repeat efficacy figures for a drug that is not approved anywhere.

Trial and paperWho took partLengthPrimary endpoint
Phase 2 · NEJM, 2023338 adults with a body-mass index (BMI) of 30 or more, or 27 to under 30 with a weight-related condition48 weeksPercentage change in body weight at 24 weeks
TRIUMPH-1 · NEJM, online 29 Sep 20262,339 adults with obesity and without diabetes, with sub-studies of 574 people with knee osteoarthritis and 243 with obstructive sleep apnoea80 weeksPercentage change in body weight; in the sub-studies, a knee-pain score (WOMAC) and the apnoea–hypopnoea index, a count of pauses and shallow breaths per hour of sleep
TRIUMPH-2 · The Lancet, online 29 Sep 20261,152 adults with type 2 diabetes and a BMI of 27 or more, at 92 centres in eight countries80 weeksPercentage change in body weight
TRIUMPH-4 · NEJM, online 8 Nov 2026445 adults without diabetes, with painful knee osteoarthritis and a BMI of at least 27; the same paper reports TRIUMPH-1’s knee sub-study68 weeksWOMAC pain score and percentage change in body weight

Adverse events. These describe Lilly’s product under trial conditions. In the phase 2 trial the most common adverse events were gastrointestinal, mostly mild to moderate, and heart rate rose, peaking at 24 weeks. In TRIUMPH-2, gastrointestinal events, low blood pressure and dysaesthesia (altered skin sensation) were more frequent than with placebo, and stopping treatment for good because of adverse events or death was more frequent in two of the three retatrutide groups. In the knee osteoarthritis trials, serious adverse events were more common with retatrutide than with placebo.

None of this describes material sold outside the trials, which has not been through them. How to read safety data like this: side effects, documented vs unknown.

04Is retatrutide approved?

No. As of 18 November 2026 it is not approved in any country.

United States. Lilly said on 29 September 2026 that it “plans to submit a Biologics License Application (BLA) in Q1 2027” to FDA. A submission asks FDA to review the evidence; it is not an approval. FDA’s page on unapproved GLP-1 drugs (content current 1 October 2026) says retatrutide and cagrilintide “cannot be used in compounding under federal law” and “are not components of FDA-approved drugs and have not been found safe and effective for any condition”.

United Kingdom. The MHRA said on 15 October 2026 that “Retatrutide has not been authorised for use in the UK” and that “Products being sold as retatrutide outside legitimate clinical trials are being supplied illegally and could pose serious risks to public health.” More: are peptides legal in the UK?

Australia. The TGA wrote on 5 November 2026 that retatrutide “is still undergoing clinical trials in humans and has not been approved by the TGA or any comparable international regulator”, and that any retatrutide product obtained outside a clinical trial “could be counterfeit”. More: are peptides legal in Australia?

Elsewhere. A JAMA news feature of 9 October 2026 on retatrutide and a second pipeline drug, zenagamtide, noted that “neither therapy has been approved by any regulatory authority in the world”.

05Why products sold online as retatrutide are not the trial drug

Every trial above tested Lilly’s product. Material sold online under the same name has not been through those trials, and regulators in the US, the UK and Australia have acted on it.

FDA. Warning letters dated 24 August 2026 to four online sellers listed their retatrutide products, labelled for research use and sold under names including “GLP-3 RT” and “GLP-3R”, among unapproved new drugs. FDA’s GLP-1 page says the agency has warned companies that “illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled ‘for research purposes’ or ‘not for human consumption’”, and says these products, sold directly to consumers, are “of unknown quality and may be harmful to their health”.

MHRA. See its 15 October 2026 statement above: products sold as retatrutide outside legitimate clinical trials “are being supplied illegally”.

TGA. In November 2026 the TGA’s laboratory tested products from one brand sold as “Retatrutide 10 mg” and found they “contained less retatrutide than stated on the label, with significant variation between samples”. The TGA concluded that consumers cannot rely on these labels to know what substance, or what amount, a product contains. Other cases: contamination and mislabeling.

A lab report can show what one tested sample contained: its identity, amount and purity. It cannot turn that sample into the product Lilly tested, or into an approved medicine. How identity is checked: mass spectrometry explained.

06What we don’t know

  • Whether any regulator will approve retatrutide, or for what. Lilly plans its US submission for the first quarter of 2027.
  • Its effect on heart and kidney outcomes. TRIUMPH-Outcomes, planned for about 10,000 adults with obesity, is listed as active, not recruiting, with primary completion expected in February 2029 (NCT06383390).
  • The full results of TRIUMPH-3, in 1,946 adults with obesity and cardiovascular disease. ClinicalTrials.gov lists it as completed (NCT05882045); we found no journal paper (PubMed, 18 Nov 2026).
  • What any vial sold online contains. A lab report shows what the tested sample held, and the TGA found one brand’s labels did not match the contents.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.

RefSources

  1. Jastreboff AM, Kaplan LM, Davies MJ, et al.; TRIUMPH-1 Investigators. [TRIUMPH-1 phase 3 trial report.] N Engl J Med, 2026;395(18):1781–1793 (online 29 Sep 2026). PMID 42814954. pubmed.ncbi.nlm.nih.gov/42814954/
  2. Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet, 2026;408(10563):1455–1472 (online 29 Sep 2026). PMID 42810372. pubmed.ncbi.nlm.nih.gov/42810372/
  3. Schnitzer TJ, Hunter DJ, Conaghan PG, et al.; TRIUMPH-4 and TRIUMPH-1-OA Investigators. [TRIUMPH-4 and TRIUMPH-1-OA phase 3 trial report.] N Engl J Med, online 8 Nov 2026. PMID 43001755. pubmed.ncbi.nlm.nih.gov/43001755/
  4. Jastreboff AM, Kaplan LM, Frías JP, et al. [Phase 2 trial report.] N Engl J Med, 2023;389(6):514–526. PMID 37366315. pubmed.ncbi.nlm.nih.gov/37366315/
  5. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet, 2022;400(10366):1869–1881. PMID 36354040. pubmed.ncbi.nlm.nih.gov/36354040/
  6. ClinicalTrials.gov. Phase 3 studies with retatrutide (LY3437943) as an intervention: 14 records, including NCT05882045 (TRIUMPH-3) and NCT06383390 (TRIUMPH-Outcomes). Registry search via API v2, read 18 Nov 2026. clinicaltrials.gov/search?intr=retatrutide&aggFilters=phase:…
  7. Eli Lilly and Company. [Press release on the TRIUMPH-2 results and the planned US submission.] Press release, Indianapolis, 29 Sep 2026; read on PR Newswire 18 Nov 2026 (investor.lilly.com returned 403). www.prnewswire.com/news-releases/lillys-triple-agonist-retat…
  8. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Web page, content current as of 1 Oct 2026; read 18 Nov 2026. www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-u…
  9. U.S. Food and Drug Administration. Warning letters 735067 (TXP Innovations LLC dba Tex Peptides), 735127 (Peak Performance Peptides), 734884 (Royal Peptides LLC) and 733652 (NuScience Peptides LLC). Warning letters, all dated 24 Aug 2026; read 18 Nov 2026. www.fda.gov/inspections-compliance-enforcement-and-criminal-…
  10. Medicines and Healthcare products Regulatory Agency. Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police. Press release, 15 Oct 2026; read 18 Nov 2026. www.gov.uk/government/news/counterfeit-weight-loss-pens-wort…
  11. Therapeutic Goods Administration. TGA testing finds unapproved peptides do not contain what their labels claim. Safety advisory, 5 Nov 2026; read on the Internet Archive capture of 15 Nov 2026, the newest (tga.gov.au timed out on 18 Nov 2026). www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  12. Rubin R. Unapproved GLP-1 drugs retatrutide and zenagamtide sold online are no bargain. JAMA Medical News, 2026;336(17):1493–1495 (online 9 Oct 2026). PMID 42853576. Paywalled; title, summary and opening read 18 Nov 2026. pubmed.ncbi.nlm.nih.gov/42853576/

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Is retatrutide approved anywhere?

No. It is not approved for any use in any country. Lilly says it plans to submit an application to FDA in the first quarter of 2027; approval would depend on FDA’s review.

Is retatrutide a GLP-1?

It activates the GLP-1 receptor, and also the GIP and glucagon receptors, which is why it is called a triple agonist. It is investigational, not an approved medicine.

What is GLP-3?

In online sales, a seller’s name for retatrutide; no PubMed title or abstract on retatrutide uses it (18 Nov 2026). FDA warning letters from August 2026 record products listed as “GLP-3 RT” and “GLP-3R”.

Can retatrutide be compounded?

Not in the US. FDA says retatrutide “cannot be used in compounding under federal law”, and that it is not a component of any FDA-approved drug.

Are products sold online as retatrutide the trial drug?

No. Every published trial tested Lilly’s product, and material sold online under the name has not been through those trials. The MHRA says products sold outside legitimate clinical trials are supplied illegally, and in November 2026 the TGA found that tested products from one brand held less retatrutide than their labels stated.

When were the TRIUMPH obesity trial results published?

TRIUMPH-1 appeared in NEJM and TRIUMPH-2 in The Lancet on 29 September 2026; the knee osteoarthritis trials followed in NEJM on 8 November 2026.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page
Further reading

Articles on this topic

Sport · WADAIs Retatrutide Banned in Sport? WADA S0 and DatesWADA’s 2026 and 2027 Lists do not name retatrutide, and WADA says an unnamed peptide may still be prohibited. Class S0 and who decides, dated.10 min readLegal status · AustraliaIs Retatrutide Legal in Australia? TGA Status (2026)Retatrutide is not approved in Australia. What the TGA says, how the Therapeutic Goods Act and Poisons Standard apply, 2026 enforcement and sport.11 min readLegal status · UKIs Retatrutide Legal in the UK? MHRA and Dates (2026)Retatrutide is not authorised in the UK, and the MHRA says selling it is illegal. Its statements, the medicines law it enforces, raids and dates.11 min readLegal status · USIs Retatrutide Legal in the US? FDA Status (2026)Retatrutide is not FDA-approved, and FDA says it cannot be used in compounding under federal law. Its statements, warning letters since 2024, dated.10 min readIdentity and historyRetatrutide History: Discovery, Trials and RegulatorsRetatrutide history from Lilly’s 2022 discovery paper to November 2026: its code and name, the phase 1 to 3 trials and the regulator actions we found.12 min readSafety recordRetatrutide Side Effects: What the Trials RecordedRetatrutide side effects by trial: most often gastrointestinal, with discontinuation rates, deaths and FDA reports. Investigational, approved nowhere.14 min readStudy explainerRetatrutide TRIUMPH Trials: Design, Measures, LimitsThe retatrutide TRIUMPH trials one by one: registry IDs, who took part, primary endpoints, papers and limits. We describe design, not results.12 min readComparisonRetatrutide vs Cagrilintide: Targets, Trials, StatusRetatrutide vs cagrilintide: investigational peptides from Lilly and Novo Nordisk with different targets and trials, neither approved in the US or EU.11 min read